Back to resultsGRK4 Polymorphisms Blood Pressure Response to Candesartan
Primary Purpose
Essential Hypertension
Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Candesartan
Sponsored by
About this trial
This is an interventional treatment trial for Essential Hypertension focused on measuring men and women, in southwestern Han Chinese
Eligibility Criteria
Inclusion Criteria:
- men and women with mild to moderate essential hypertension in southwestern Han Chinese
Exclusion Criteria:
- subjects unwilling to participate or subjects did not have all measurement required,
- subjects who were on medications, which affect blood pressure or
- whose DNA failed to amplify and 8 with errors in Mendelian segregation
Sites / Locations
- Department of Cardiology, Daping Hospital, The Third Military Medical UniversityRecruiting
Arms of the Study
Arm 1
Arm Type
No Intervention
Arm Label
candesartan
Arm Description
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
Outcomes
Primary Outcome Measures
The subjects with GRK4 varirants may exert different response during 4 weeks of treatment with candesartan in patients with essential hypertension
Secondary Outcome Measures
Full Information
NCT ID
NCT01629225
First Posted
June 24, 2012
Last Updated
November 17, 2014
Sponsor
Third Military Medical University
1. Study Identification
Unique Protocol Identification Number
NCT01629225
Brief Title
GRK4 Polymorphisms Blood Pressure Response to Candesartan
Study Type
Interventional
2. Study Status
Record Verification Date
June 2013
Overall Recruitment Status
Unknown status
Study Start Date
July 2013 (undefined)
Primary Completion Date
July 2015 (Anticipated)
Study Completion Date
July 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Third Military Medical University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.
Detailed Description
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Essential Hypertension
Keywords
men and women, in southwestern Han Chinese
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
Participant
Allocation
N/A
Enrollment
500 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
candesartan
Arm Type
No Intervention
Arm Description
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
Intervention Type
Drug
Intervention Name(s)
Candesartan
Other Intervention Name(s)
GRK4 polymorphisms and essential hypertrension
Intervention Description
To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
Primary Outcome Measure Information:
Title
The subjects with GRK4 varirants may exert different response during 4 weeks of treatment with candesartan in patients with essential hypertension
Time Frame
two years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
men and women with mild to moderate essential hypertension in southwestern Han Chinese
Exclusion Criteria:
subjects unwilling to participate or subjects did not have all measurement required,
subjects who were on medications, which affect blood pressure or
whose DNA failed to amplify and 8 with errors in Mendelian segregation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yu changqing, Doctor
Phone
02368731850
Email
changqingyu-2@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zeng Chunyu, Doctor
Organizational Affiliation
TMMU
Official's Role
Study Director
Facility Information:
Facility Name
Department of Cardiology, Daping Hospital, The Third Military Medical University
City
Chongqing
ZIP/Postal Code
400042
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yu Changqing, MD
Email
changqingyu-2@163.com
12. IPD Sharing Statement
Citations:
PubMed Identifier
26871769
Citation
Cai Y, Yang Y, Chen X, He D, Zhang X, Wen X, Hu J, Fu C, Qiu D, Jose PA, Zeng C, Zhou L. Circulating "LncPPARdelta" From Monocytes as a Novel Biomarker for Coronary Artery Diseases. Medicine (Baltimore). 2016 Feb;95(6):e2360. doi: 10.1097/MD.0000000000002360.
Results Reference
derived
PubMed Identifier
26201019
Citation
Yang Y, Cai Y, Wu G, Chen X, Liu Y, Wang X, Yu J, Li C, Chen X, Jose PA, Zhou L, Zeng C. Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease. Clin Sci (Lond). 2015 Oct 1;129(8):675-85. doi: 10.1042/CS20150121. Epub 2015 Jun 11.
Results Reference
derived
Learn more about this trial
GRK4 Polymorphisms Blood Pressure Response to Candesartan
We'll reach out to this number within 24 hrs